Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €20.92 EUR
Change Today -0.151 / -0.72%
Volume 6.7K
HNL On Other Exchanges
Symbol
Exchange
Xetra
As of 4:35 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

dr hoenle ag (HNL) Snapshot

Open
€21.08
Previous Close
€21.07
Day High
€21.30
Day Low
€20.61
52 Week High
03/17/15 - €21.82
52 Week Low
04/1/14 - €13.58
Market Cap
115.3M
Average Volume 10 Days
18.7K
EPS TTM
€1.17
Shares Outstanding
5.5M
EX-Date
03/23/15
P/E TM
17.9x
Dividend
€0.50
Dividend Yield
2.39%
Current Stock Chart for DR HOENLE AG (HNL)

Related News

No related news articles were found.

dr hoenle ag (HNL) Related Businessweek News

No Related Businessweek News Found

dr hoenle ag (HNL) Details

Dr. Hönle AG, together with its subsidiaries, develops, produces, and sells UV radiation systems, lamps, and adhesives and casting compounds for industrial applications worldwide. It operates in three segments: Equipment and Systems, Glass and Lamps, and Adhesives. The company’s products include UV equipment and systems, UV measurement systems, LED units, UV lamps, electronic power supply systems, UV strip/UV scan, and UV adhesives. Its products are used in sheed-fed offset printing, photovoltaic and sun simulation, curing of adhesives and pottants, disinfection, UV measurement technology, UV lamps, fluorescence testing, and inerted systems. The company’s products are also used in inkjet printing, Web offset printing, flexo print, and finishing/coating applications. Dr. Hönle AG was founded in 1976 and is headquartered in Gräfelfing, Germany.

522 Employees
Last Reported Date: 02/20/15
Founded in 1976

dr hoenle ag (HNL) Top Compensated Officers

Chief Financial Officer, Managing Director, D...
Total Annual Compensation: €407.0K
Managing Director of Sales & Technology and M...
Total Annual Compensation: €406.0K
Compensation as of Fiscal Year 2014.

dr hoenle ag (HNL) Key Developments

Dr. Hönle AG Announces Earnings Results for the First Quarter of Fiscal Year 2015; Provides Earnings Guidance for the Year 2015

Dr. Hönle AG announced earnings results for the first quarter of fiscal year 2015. For the quarter, Sales revenues jumped 7.6 % to €21,790,000 and the corporate group succeeded in improving the operating result (EBIT) by 19.6 % to €2,653,000. Earnings before tax rose by 20.2 % to €2,520,000 and consolidated earnings saw a 19.4 % increase to €1,801,000. This translates into earnings per share of €0.32 against €0.28 a year ago. Net profit on sales climbed from 7.5 % to 8.3 % in the same period. The company assumes sales revenues of between €85 and €95 million and an operating result of between €12 and €14 million for the financial year 2015.

Dr. Hönle AG to Report Q1, 2015 Results on Feb 26, 2015

Dr. Hönle AG announced that they will report Q1, 2015 results on Feb 26, 2015

Dr. Hönle AG Reports Earnings Results for the Financial Year 2014; Provides Earnings Guidance for the Financial Year 2015

Dr. Hönle AG reported earnings results for the financial year 2014. For the year, the company announced sales revenues climbed 6.2 % to EUR 82,090,000. The operating result saw a 23.1 % increase to EUR 9,483,000 in the same period. In the previous year, special financial income-related influences amounting to EUR 1,491 led to an increase in the pre-tax result and consolidated net income for the year. At EUR 8,967,000, EBT (pre-tax result) was therefore only 3.8 % up on the previous year whereas the consolidated result dropped by 3.2 % to EUR 6,495,000. This translates into earnings per share of EUR 1.13 compared to EUR 1.20 a year ago. Adjusted for the special influences, EBT was up 25.5 % and the consolidated result was up 24.4 % on the previous year’s level. The Management aims at sales of between EUR 85 million and EUR 95 million and an operating result of between EUR 12 million and EUR 14 million for financial year 2014/2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HNL:GR €20.92 EUR -0.151

HNL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for HNL.
View Industry Companies
 

Industry Analysis

HNL

Industry Average

Valuation HNL Industry Range
Price/Earnings 16.1x
Price/Sales 1.2x
Price/Book 2.1x
Price/Cash Flow 11.5x
TEV/Sales 1.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DR HOENLE AG, please visit www.hoenle.de. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.